The zebra is out of the barn! Excited to share our Guest Editor's Page in @JACCJournals #JACCCaseReports on Current State of Affairs and Promise for the Future in ATTR @IRajapreyar @RJAjr @JGrapsa @TJHeartFellows @TJUHospital

RT @hmkyale: 🚨 NEW in @JACCJournals: Despite global initiatives, 2° prevention medication use in CVD stagnant or declining in most income-l…

RT @ACCinTouch: Mechanical surgical AVR was associated w/ ⬇️ all-cause mortality in patients ≤60 years old compared w/ bioprosthetic AVR, a…

RT @KPHeartDoc: LA HTN is key in HF and HFpEF, driving symptoms like pulmonary congestion & RH dysfunction. LA shunting therapies (implant-…

RT @KPHeartDoc: Are beta-blockers beneficial, harmful, or neutral in HFpEF? TBD.

RT @VincentRK: MGUS: With increased testing and with mass spectrometry to detect monoclonal (M) proteins, we are increasingly finding small…

RT @KPHeartDoc: LVADs improve survival & QoL for end-stage HF patients, but functional gains are modest. Cardiac rehab post-implant boosts…

RT @TheJHLT: De novo #Htx patients randomized to everolimus and low dose CNI followed by CNI free therapy sustained significantly better lo…

RT @TheJHLT: Going the Distance: Long-term follow-up of the randomized, prospective Scandinavian heart transplant everolimus de novo study…

RT @DocSavageTJU: Novel sign of #Takotsubo CM=“Dynamic coronary hinge” at intersection of hyperdynamic & akinetic wall segments @mmamas1973…

RT @MathewMaurer: @ColumbiaMed Contact Fellowship Program Coordinator Stephen Helmke at sh2669@cumc.columbia.edu

RT @MathewMaurer: Looking for a cardiology career? Cardiac Amyloidosis Program seeking candidates for 1 year post-doctoral fellowship at @C…

RT @EJHFEiC: 🗞️ Outpatient worsening #HeartFailure and mortality in transthyretin amyloid cardiomyopathy @ESC_Journals @GiuseppeGalati_…

RT @AndrewJSauer: 🔥 fresh press 📝 led by @AminYehyaMD on contemporary role for ICD in era of improved GDMT. Implantable cardioverter-defi…

@maz_hanna @JACCJournals @IRajapreyar @RJAjr @JGrapsa @TJHeartFellows @TJUHospital @AHajduczok @DavidWienerMD @MasriAhmadMD @bhtrachtenberg @BrettSperryMD @MathewMaurer @mahwash_kassi @DrSFeldman @Amyloidosis_ARC Thank you 🙏

RT @JNCjournal: Favorable changes in quantitative 99mTc-PYP myocardial uptake on transthyretin stabilization therapy @SVijayakumarMD @mdica…

Exciting news from @US_FDA as we have a new drug approved for #Amyloidosis. Excited for more choices for our patients @Amyloidosis_ARC @BridgeBioPharma Original data from ATTRIBUTE-CM @NEJM

Great collaborative effort on review of echo in #PulmonaryEmbolism @LoyolaMedPERT @jeff_pert @darki_amir @EstefaniaOS @FMaeWestMD @JessHotelling

RT @fbinegotiator: I’m the former lead FBI Hostage Negotiator. These days I teach negotiation and communication skills for a living. Retw…

RT @NirUrielMD: Our 2024 @NYPCUCVI Heart Failure Research Institute Symposium is tomorrow, Nov 1st from 2-6 PM Both live and virtual optio…

RT @GBarnesMD: In case you missed it, the PEERLESS trial results were presented at #TCT24 yesterday and published in @CircAHA. https://t.co…